Please enable Javascript
Myelofibrosis
The latest news, research, and perspectives in myelofibrosis (MF). A primary subtype of myeloproliferative neoplasms (MPNs), this rare blood cancer scars the bone marrow so that it cannot properly produce blood cells.
Advertisement
Selinexor Plus Ruxolitinib Well Tolerated in JAKi-Naïve Patients with Myelofibrosis
Melissa Badamo
Myelofibrosis
|
November 17, 2023
Researchers also observed potential disease modification via rapid stabilization of platelets and stable hemoglobin levels.
Read More
Final Analysis of IFNα Versus Conventional Hydroxyurea in Myeloproliferative Neoplasms
Patrick Daly
Myelofibrosis
|
November 16, 2023
There were no significant differences in response rates with pegylated interferon-alpha versus hydroxyurea in MPN treatment.
Read More
Pelabresib Plus Ruxolitinib Is a Promising Treatment Regimen for Myelofibrosis
Melissa Badamo
Myelofibrosis
|
November 16, 2023
The trial is based on “compelling data” from arm III of the ongoing phase II MANIFEST study.
Read More
Interim Analysis Confirms Efficacy, Tolerability of Ruxolitinib in Myelofibrosis
Melissa Badamo
Myelofibrosis
|
October 13, 2023
82.5% of MF patients experienced rapid significant decreases in palpable spleen size after two months of ruxolitinib therapy.
Read More
Which Factors Predict Long-term Ruxolitinib Use in Myelofibrosis?
Melissa Badamo
Myelofibrosis
|
October 13, 2023
The median duration of therapy is around three years in patients with intermediate or high-risk MF.
Read More
Is Allogeneic HSCT an Effective Option in CALR-Mutated Myelofibrosis?
Patrick Daly
Myelofibrosis
|
October 12, 2023
The analysis included 346 patients with CALR-mutated MF who were transplanted in 123 centers between 2005 and 2019.
Read More
Advertisement
Reflecting on Myelofibrosis Awareness Day
Sangeetha Venugopal, MD
Myelofibrosis
|
September 20, 2023
Myelofibrosis Awareness Day is marked on September 20th each year.
View More
First-line Selinexor, Ruxolitinib Shows Ongoing Promise for Myelofibrosis
Leah Lawrence
Meeting News
|
September 19, 2023
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
Read More
Luspatercept Improved Anemia, Transfusion Burden in Myelofibrosis
Leah Lawrence
Myelofibrosis
|
September 19, 2023
The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy.
Read More
Pacritinib Spleen Response Yielded OS Benefit in Cytopenic Myelofibrosis
Leah Lawrence
Myelofibrosis
|
September 18, 2023
In PERSIST-2, treatment with pacritinib demonstrated a significant SVR benefit compared with the best available therapy, incl
Read More
FDA Approves Momelotinib in Patients with Myelofibrosis Plus Anemia
Leah Sherwood
Myelofibrosis
|
September 16, 2023
Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease.
Read More
Researchers Review Safety Profile of Ruxolitinib in Myelofibrosis
Cecilia Brown
Myelofibrosis
|
August 21, 2023
Ruxolitinib, an oral JAK1/JAK2 inhibitor, initially received FDA approval in 2011.
Read More
Study Investigates Mechanism Behind Anemia Benefit of Pacritinib
Cecilia Brown
Myelofibrosis
|
August 21, 2023
Researchers conducted the study because the mechanism by which pacritinib improves anemia has not been elucidated.
Read More
Should a BET Inhibitor Be Added to JAK Inhibitor Therapy?
Cecilia Brown
Myelofibrosis
|
August 18, 2023
Researchers conducted an indirect comparison analysis of multiple clinical trials to address the question.
Read More
FDA Grants Fast Track Designation to Selinexor in Myelofibrosis Treatment
Leah Sherwood
Myelofibrosis
|
August 9, 2023
In June 2023, the manufacturer of the drug initiated XPORT-MF-034, a pivotal phase III clinical trial.
Read More
SOHO Ambassador Program Strengthens Global HemOnc Community
Leah Sherwood
Indolent B-Cell Lymphoma
|
July 17, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Read More
Phase II Study Evaluates Ropeginterferon Alfa 2b in Lower-Risk, Early Primary Myelofibrosis
Cecilia Brown
Myelofibrosis
|
July 14, 2023
At a median follow-up of 55 weeks, 90% of patients completed 24 weeks of treatment and 56% completed 48 weeks of treatment.
Read More
Does Bone Marrow Fibrosis Impact the Response to Ruxolitinib in Primary Myelofibrosis?
Cecilia Brown
Myelofibrosis
|
July 13, 2023
Initiation of ruxolitinib therapy within two years of diagnosis was associated with increased response rates in all patients.
Read More
MAJIC Study Underscores Importance of Ruxolitinib in PV Treatment
Cecilia Brown
Myeloproliferative Neoplasms
|
June 20, 2023
Just under half (43%) of patients receiving ruxolitinib achieved a CR, while 26% achieved a CR on the best available therapy.
Read More
Spleen Volume Reduction Predicts Survival in Patients with Myelofibrosis Receiving Pacritinib
Cecilia Brown
Myeloproliferative Neoplasms
|
June 16, 2023
However, achieving a spleen volume reduction on the best available therapy was not linked with improved survival.
Read More
Load More
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACP
Editor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MD
Associate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MD
Associate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MD
Associate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MD
Associate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MD
Associate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPH
Associate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer